We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
CAT No: PI-006
CAS No: 136054-22-3
Synonyms/Alias: 136054-22-3;[D-Lys3]-GHRP-6;D-Lys3-GHRP-6;(D-Lys3)-GHRP-6;(2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2R)-6-amino-2-[[(2R)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]hexanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide;H-HIS-D-TRP-D-LYS-TRP-D-PHE-LYS-NH2;[D-Lys3]GHRP-6;[His1, D-Lys3, Lys6]-GHRP;MFCD00214665;His-D-Trp-D-Lys-Trp-D-Phe-Lys-NH2;[D-Lys] GHRP-6;GTPL11814;AKOS024456859;NCGC00167345-01;FL108884;DB-277002;G78085;[D-Lys3]-GHRP-6, synthetic, lyophilized powder;L-HISTIDYL-D-TRYPTOPHYL-D-LYSYL-L-TRYPTOPHYL-D-PHENYLALANYL-L-LYSINAMIDE;
Chemical Name: (2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2R)-6-amino-2-[[(2R)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]hexanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C49H63N13O6 |
M.W/Mr. | 930.1 |
Sequence | One Letter Code:HWKWFK Three Letter Code:H-His-D-Trp-D-Lys-Trp-D-Phe-Lys-NH2 |
InChI | InChI=1S/C49H63N13O6/c50-20-10-8-18-39(44(53)63)58-47(66)41(22-30-12-2-1-3-13-30)61-49(68)43(24-32-27-56-38-17-7-5-15-35(32)38)62-46(65)40(19-9-11-21-51)59-48(67)42(23-31-26-55-37-16-6-4-14-34(31)37)60-45(64)36(52)25-33-28-54-29-57-33/h1-7,12-17,26-29,36,39-43,55-56H,8-11,18-25,50-52H2,(H2,53,63)(H,54,57)(H,58,66)(H,59,67)(H,60,64)(H,61,68)(H,62,65)/t36-,39-,40+,41+,42+,43-/m0/s1 |
InChI Key | MGSNWNLPMHXGDD-DFWOJPNQSA-N |
Canonical SMILES | C1=CC=C(C=C1)CC(C(=O)NC(CCCCN)C(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CCCCN)NC(=O)C(CC4=CNC5=CC=CC=C54)NC(=O)C(CC6=CN=CN6)N |
Isomeric SMILES | C1=CC=C(C=C1)C[C@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CC4=CNC5=CC=CC=C54)NC(=O)[C@H](CC6=CN=CN6)N |
4. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment
5. The spatiotemporal control of signalling and trafficking of the GLP-1R
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.